Sorin Group

Sorin receives CE Mark approval of cobalt chrome Carbostent to treat cardiovascular disease

Published in Physician Law Weekly, May 3rd, 2006

Sorin Group, a European medical technology company specializing in the treatment of cardiovascular diseases, announced that it has received CE Mark approval for its new cobalt chrome coronary carbostent, the Chrono stent, which will be fully released in Europe and all the CE mark countries.

Since the introduction of colbolt chorome as a revolutionary new material for coronary stents, it has demonstrated excellent characteristics including higher mechanical strength and radiopacity than stainless steel. Other advantages include a new stent design engineered to provide more flexibility, and a new delivery system PTS (progressive transition system), which is designed to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly

Source: Physician Law Weekly (2006-05-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry